neoX is a biotech company that combines artificial intelligence (AI) with biophysics for drug research and development. neoX focuses on the research and development of macromolecular drugs and multispecific drugs, especially in the field of immuno-oncology. It has developed a sophisticated platform for early discovery of therapeutics by characterizing protein-protein interactions (PPI). neoX has established cooperation with biomedical companies globally to accelerate drug R&D pipelines.
Total Funding: $40 M
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2018
Database Development Engineer
Beijing, Beijing
Big Data Analysis Engineer
Beijing, Beijing
Cloud Platform Development Engineer
Beijing, Beijing
Cellular Immunologist
Beijing, Beijing
Scientific Computing Software Development Engineer
Beijing, Beijing